右美托咪定用于心脏瓣膜手术成年患者谵妄的随机对照试验。
A randomised controlled trial of dexmedetomidine for delirium in adults undergoing heart valve surgery.
作者信息
Wang H-B, Jia Y, Zhang C-B, Zhang L, Li Y-N, Ding J, Wu X, Zhang Z, Wang J-H, Wang Y, Yan F-X, Yuan S, Sessler D I
机构信息
Department of Anaesthesiology, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Anaesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen (Sun Yat-sen Cardiovascular Hospital, Shenzhen), Shenzhen, China.
出版信息
Anaesthesia. 2023 May;78(5):571-576. doi: 10.1111/anae.15983. Epub 2023 Feb 16.
Dexmedetomidine might reduce delirium after cardiac surgery. We allocated 326 participants to an infusion of dexmedetomidine at a rate of 0.6 μg kg for 10 min and then at 0.4 μg.kg .h until the end of surgery; 326 control participants received comparable volumes of saline. We detected delirium in 98/652 (15%) participants during the first seven postoperative days: 47/326 after dexmedetomidine vs. 51/326 after placebo, p = 0.62, adjusted relative risk (95%CI) 0.86 (0.56-1.33), p = 0.51. Postoperative renal impairment (Kidney Disease Improving Global Outcomes stages 1, 2 and 3) was detected in 46, 9 and 2 participants after dexmedetomidine and 25, 7 and 4 control participants, p = 0.040. Intra-operative dexmedetomidine infusion did not reduce the incidence of delirium after cardiac valve surgery but might impair renal function.
右美托咪定可能会降低心脏手术后谵妄的发生率。我们将326名参与者分配至以0.6μg/kg的速率输注右美托咪定10分钟,然后以0.4μg·kg·h的速率持续输注直至手术结束;326名对照参与者接受了等量的生理盐水。在术后的前七天,我们在98/652(15%)名参与者中检测到谵妄:右美托咪定组为47/326,安慰剂组为51/326,p = 0.62,调整后的相对风险(95%CI)为0.86(0.56 - 1.3),p = 0.51。右美托咪定组术后出现肾功能损害(改善全球肾脏病预后组织1、2和3期)的参与者分别为46、9和2名,对照组分别为25、7和4名,p = 0.040。术中输注右美托咪定并不能降低心脏瓣膜手术后谵妄的发生率,但可能会损害肾功能。